Will Liquid Biopsies Transform Oncology Clinical Trials?
01 August 2016
Epic Sciences says it has developed a technology that CEO Murali Prahalad believes will transform oncology trials by identifying and characterizing circulating tumor cells. Those cells have been long recognized as a key part of cancer metastasis. Tumors shed these cells into the circulatory system where they then travel to different parts of the body and, under the right conditions, become the genesis of new tumors.
Pfizer Partners with NovaMedica to Build Manufacturing Unit in Russia
20 July 2016
Pfizer Inc. (NYSE: PFE) is currently in the process of developing several manufacturing units in a number of geographical territories all over the world. Just recently, the pharmaceutical giant inked its third major deal in the in the past couple of years. This huge deal involves a partnership with NovaMedica of Russia to establish a manufacturing facility in the country.
Pfizer agrees to license 30 products to Russian pharma company
19 July 2016
US drugs company Pfizer has entered into a manufacturing and licensing agreement with Russian pharmaceutical company NovaMedica. Pfizer has proposed to invest in NovaMedica’s construction of a new manufacturing plant in the Kaluga region.
Pfizer, NovaMedica Announce Strategic Partnership in Russia
19 July 2016
Pfizer, one of the world’s premier biopharmaceutical companies and NovaMedica, a Russian pharmaceutical company established by Rusnano and Domain Associates, have announced the start of a long-term strategic partnership to locally manufacture and bring to the Russian market a number of important medicines. The first step will be the construction of a modern pharmaceutical manufacturing plant located in the Vorsino industrial park, Kaluga Region.
Pfizer Inc. (PFE) Ready to Reconnoiter Russian Therapeutic Markets
18 July 2016
As restrictions in the Western countries rise and growth remains stagnant, Pfizer has taken a wise step to slowly and steadily enter Russia with the establishment of a manufacturing unit. Pfizer Inc. is in the process to develop manufacturing facilities in numerous geographical territories around the globe. Recently, the drug maker signed its third mega deal in the past several years, which is an agreement with Russia’s NovaMedica to build a manufacturing unit.
Pfizer strikes second deal this year for drug production in Russia
18 July 2016
Pfizer was a little behind some of its peers in establishing local manufacturing in Russia but it's on a roll now, having just announced its third deal in several years. It is hammering out an agreement with Russia’s NovaMedica for a new manufacturing plant.
Atlas Genetics mandates UBS for up to USD 30m raise — source
15 July 2016
Atlas Genetics (AG), a UK-based, PE-backed point-of-care (POC) diagnostics company, is looking to raise up to USD 30m to fund clinical trials and commercialization, a source familiar with the situation said. The company has developed ultra-rapid, low cost, multiple analyte detection technology for POC use to screen the presence of sexually transmitted infections (STIs) and hospital acquired infections (HAIs).
Pfizer's Russia Deal Shows Country Still Open To Western Business
15 July 2016
U.S. multinational drug maker Pfizer PFE +1.68% is laying down a new foundation in Russia, with a joint venture announced on Wednesday to produce pharmaceuticals domestically.
Pfizer links with NovaMedica to produce and market drugs in Russia
15 July 2016
US pharma giant Pfizer (NYSE: PFE) and NovaMedica, a company established by Russian high-technology investment fund Rusnano and American venture health care fund Domain Associates in 2012, have entered into an agreement to cooperate, signalling the development of a new partnership, to bring important medicines to the Russian market.
EyewireTV – FDA Approves Raindrop Inlay; Humira for Uveitis Treatment
08 July 2016
In this week’s EyewireTV, ReVision Optics receives FDA approval for the Raindrop Near Vision Inlay, the first implantable device that changes the shape of the cornea to achieve improved vision; and the FDA approves Humira (adalimumab) for the treatment of noninfectious intermediate and posterior uveitis and panuveitis. Also, Bausch + Lomb and Nicox announce that the results of a phase 3 study of glaucoma drug candidate latanoprostene bunod have been published in the American Journal of Ophthalmology.
05 November 2024
03 November 2024
October 10 – World Mental Health Day
10 October 2024
Siberian State Medical University and Skoltech to start production of bone tissue fillers
22 November 2024
Sechenov University is creating a digital drug reference book
21 November 2024
Skills shortage still holding back pharma's digital transformation: survey
21 November 2024
Trials for Russia’s first CAR-T drug “Utzhefra” have started
20 November 2024